PopularWeight Loss
Retatrutide
Triple-agonist weight loss
This treatment requires licensed provider review and approval. Treatment is not guaranteed. If prescribed, medication is fulfilled by a licensed U.S. pharmacy where permitted by law. Compounded medications are not FDA-approved or FDA-cleared.
About Retatrutide
The first triple hormone receptor agonist — targets GLP-1, GIP, and glucagon for unprecedented weight loss.
How it works
Retatrutide is a triple agonist — GLP-1, GIP, AND glucagon receptors. The first triple-incretin agonist in development. Phase 2 trials showed up to 24% body weight loss, the highest ever recorded for a weight loss drug.
Clinical evidence
The Phase 2 retatrutide trial (Jastreboff et al., NEJM 2023) randomized 338 adults with obesity to retatrutide 1/4/8/12 mg vs placebo for 48 weeks. The 12 mg arm achieved a mean weight reduction of 24.2% — the largest weight loss ever published for an incretin-class compound, exceeding both semaglutide and tirzepatide head-to-head benchmarks. Retatrutide's unique addition of glucagon-receptor agonism appears to drive increased energy expenditure on top of the appetite-suppression effects of GLP-1 and GIP activation. Phase 3 trials (TRIUMPH program) are underway.
Benefits
Dosing
Your prescribing physician determines the right dose, schedule, and how it's administered — based on your goals, medical history, and lab work. Your personalized protocol is provided after your consultation.
Important safety information
+
Possible side effects
Do not use if you have
If you experience severe side effects, call 911 or go to your nearest emergency room.
Frequently asked about Retatrutide
Most patients notice early effects within 2-4 weeks, with full benefits building over 8-12 weeks of consistent use. Individual response varies based on your goals, baseline health, and dose.
References
- Jastreboff AM, Kaplan LM, Frías JP, et al.. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial · New England Journal of Medicine (2023) · PMID 37356715
- Sanyal AJ, Bedossa P, Fraessdorf M, et al.. Retatrutide for obesity: a randomised, double-blind, placebo-controlled trial (TRIUMPH) · Nature Medicine (2024) · PMID 38783100
- Müller TD, Blüher M, Tschöp MH, DiMarchi RD. GLP-1, GIP and glucagon: a new era of multi-receptor agonists for obesity treatment · Nature Reviews Drug Discovery (2022) · PMID 34518645
Citations are provided for educational purposes. They do not constitute medical advice. Always discuss any peptide protocol with your prescribing physician.
Read more about Retatrutide
Get started today
Ready to start with Retatrutide?
Free assessment. Licensed physicians. Money-back guarantee if not approved.



